The goal of this clinical trial is to determine the safety and feasibility of nasal delivery of human dental follicle mesenchymal stem cell-derived exosomes in the treatment of negative symptoms of treatment-resistant schizophrenia. It will also learn about the preliminary efficacy of the exosomes. The main questions it aims to answer are: Is the safety of the exosomes enough for participants? Is the feasibility of nasal delivery of exosomes for participants? Do the exosomes exert any benefits on the negative symptoms of treatment-resistant schizophrenia? Participants will: Take a nasal spray of exosomes twice weekly for 2 months Take vital sign checks every day, regular visits for an interview, and lab examinations
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
Nasal delivery of exosomes derived from human dental follicle mesenchymal stem cells (1×10\^9, 2×10\^9, 4×10\^9, 8×10\^9, 16×10\^9) twice weekly for eight weeks
The incidence and severity of adverse events (AE) and serious adverse events (SAE).
Time frame: week 0, 2, 4, 8, 12, 16, 20, and 24
Incidence of dose-limiting toxicity (DLT)
Specific toxic reactions related to the investigational drug that occur during the DLT observation period (within 28 days after a single administration)
Time frame: The observation period for DLT is within 28 days after a single administration
The incidence rate of abnormal laboratory tests
Blood routine, liver and kidney function (elevated ALT/AST, elevated creatinine, etc.), myocardial enzyme spectrum, inflammatory factors, allergic indicators (IgE)
Time frame: Week 0, 2, 4, 8, 12, 16, 20, and 24
The incidence of abnormal vital signs and electrocardiogram (ECG)
Time frame: Week 0, 2, 4, 8, 12, 16, 20, and 24
Drug administration completion rate
Time frame: week 8
Changes in the total score and negative symptom factor score of the PANSS scale
Time frame: week 0, 4, 8, 12, and 24
Changes in the total score and subscale scores of SANS (Negative Symptom Rating Scale)
Time frame: week 0, 4, 8, 12, and 24
Changes in the Clinical General Impression Scale - Severity (CGI-S) score
Time frame: Week 0, 4, 8, 12, 24
Changes in the Calgary Schizophrenia and Depression Scale (CDSS) score
Time frame: Week 0, 4, 8, 12, 24
Changes in the Montreal Cognitive Assessment Scale (MoCA) score
Time frame: week 0, 4, 8, 12, 24
Changes in the completion time of connection test A/B (TMT-A/B)
Time frame: week 0, 4, 8, 12, 24
Score changes of the Digit Span Test
Time frame: week 0, 4, 8, 12, 24
Changes in Language Learning and Memory Test (VLMT) scores
Time frame: week 0, 4, 8, 12, 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.